Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

CLL/SLL Clinical Trial

— AETHER  

Official title:

A Prospective Randomized Phase I/II Trial of Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05791409
• Other study ID #: HO165 CLL
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 10, 2024
• Est. completion date: November 2032

Study information

• Verified date: April 2024
• Source: Stichting Hemato-Oncologie voor Volwassenen Nederland
• Contact: Arnon Kater
• Phone: +31 6-11491753
• Email: a.p.kater[@]amsterdamumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: November 2032
• Est. primary completion date: March 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented relapsed or refractory CLL or SLL (SLL in phase II part only) following at least one systemic 1st-line treatment
• Requiring treatment according to IWCLL criteria (appendix A);
• Age at least 18 years;
• ECOG/WHO performance status 0-2;
• In case of prior venetoclax treatment, enrollment can only occur at least 24 months after end of treatment and patients must not have progressed during venetoclax treatment;
• Adequate BM function defined as:
• Hemoglobin >5.6 mmol/l or Hb > 9 g/dL, unless low Hb is directly attributable to CLL infiltration of the BM, proven by BM biopsy;
• Absolute neutrophil count (ANC) >1.0 x 109/L (1,000/µL), unless low ANC is directly attributable to CLL infiltration of the BM, proven by BM biopsy;
• Platelet count >30 x 109/L (30,000/µL), unless low platelets is directly attributable to CLL infiltration in the BM;
• Estimated Glomerular Filtration Rate (eGFR) (MDRD) or estimated creatinine clearance (CrCl) = 50ml/min (Cockcroft-Gault appendix F);
• Adequate liver function as indicated:
• Serum aspartate transaminase (ASAT) and alanine transaminase (ALAT) = 3.0 x upper limit of normal (ULN);
• Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or controlled autoimmune hemolytic anemia);
• Prothrombin time (PT)/International normal ratio (INR) <1.5x ULN and activated partial thromboplastin time (aPTT) <1.5 x ULN; unless receiving anticoagulation;
• Negative serological testing for hepatitis B virus (HBV) (Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) negative) and hepatitis C virus (hepatitis C antibody). Patients who are positive for anti-HBc or hepatitis C antibody may be included if they have a negative PCR within 6 weeks before enrollment. Those who are PCR positive will be excluded; Please note: For patients positive for anti-HBc, HBV-DNA PCR has to be repeated every month until 12 months after last dose of study treatment.
• Patient is able and willing to adhere to the study visit schedule and other protocol requirements;
• Patient is capable of giving informed consent;
• Written informed consent.

Exclusion Criteria:

• Active CLL/SLL directed therapy within the last 14 days;
• Prior treatment with a CD3 × CD20 bispecific antibody or CAR T-cell therapy
• Transformation of CLL (Richter's transformation);
• Prior allogeneic stem cell transplantation and/or solid organ transplantation;
• Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML);
• Malignancies other than CLL currently requiring systemic therapy or not treated in curative intention or showing signs of progression after curative treatment;
• Known allergy to xanthine oxidase inhibitors and/or rasburicase;
• History of drug-specific hypersensitivity or anaphylaxis to any study drug (including active product or excipient components);
• Active bleeding or uncontrolled severe bleeding diathesis (e.g., hemophilia or severe von Willebrand disease);
• Active fungal, bacterial, and/or viral infection CTCAEgrade > 1; Please note: active controlled as well as chronic/recurrent infections are at risk of reactivation/infection during treatment;
• Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, auto-immune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.);
• Patient known to be HIV-positive;
• Patient requiring treatment with a strong cytochrome P450 (CYP) 3A inhibitor/inducer (see appendix J) or anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists;
• CTCAE grade III-IV cardiovascular disease including but not limited to:
• Unstable or uncontrolled disease/condition related to or affecting cardiac function, eg, unstable angina, congestive heart failure grade III or IV as classified by the New York Heart Association (see appendix E), uncontrolled clinically significant cardiac arrhythmia (CTCAE grade II or higher), or clinically significant electrocardiogram (ECG) abnormalities.
• Myocardial infarction, intracranial bleed, or stroke within the past 6 months.
• Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >480 msec. NOTE: this criterion does not apply to subjects with a left bundle branch block.
• Stroke or intracranial hemorrhage within 6 months prior to registration.
• Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D);
• Severe neurological or psychiatric disease (CTCAE grade III-IV, see appendix D);
• Neuropathy > CTCAE grade II
• Patient who has difficulty with or are unable to swallow oral medication, or have significant gastrointestinal disease that would limit absorption of oral medication;
• Vaccination with live vaccines within 28 days prior to registration;
• Use of any other experimental drug or therapy within 28 days of registration;
• Major surgery within 28 days prior to registration;
• Pregnant women and nursing mothers;
• Fertile men or women of childbearing potential unless: (1) surgically sterile or = 2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method such as oral contraceptives, intrauterine device, sexual abstinence or combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) during study treatment and for 12 months after last dose of epcoritamab and 30 days after last dose of venetoclax;
• Previous participation in the HOVON 139 CLL or HOVON 140 CLL trial and eligible for and willing to participate in the HOVON 159 CLL trial;
• Current participation in other clinical trial with medicinal products;
• Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Related Conditions & MeSH terms

• CLL/SLL

Intervention

Drug:
• Epcoritamab
Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
• Venetoclax
All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.

Locations

Country	Name	City	State
Belgium	BE-Antwerpen-ZNASTUIVENBERG	Antwerpen
Belgium	BE-Roeselare-AZDELTA	Roeselare
Denmark	DK-Aalborg-ALBOGUH	Aalborg
Denmark	DK-Copenhagen-RIGSHOSPITALET	Copenhagen
Denmark	DK-Odense-OUH	Odense
Germany	DE-Berlin-HELIOSBERLINBUCH	Berlin
Germany	DE-Freiburg-UNIKLINIKFREIBURG	Freiburg
Germany	DE-Greifswald-UNIGREIFSWALD	Greifswald
Germany	DE-Köln-UKKOELN	Köln
Germany	DE-Munster-GEMEINSCHAFTSPRAXIS	Munster
Germany	DE-Stuttgart-RBK	Stuttgart
Germany	DE-Ulm-UNIKLINKULM	Ulm
Netherlands	NL-Alkmaar-NWZ	Alkmaar
Netherlands	NL-Amersfoort-MEANDERMC	Amersfoort
Netherlands	NL-Amsterdam-AMC	Amsterdam
Netherlands	NL-Den Bosch-JBZ	Den Bosch
Netherlands	NL-Den Haag-HAGA	Den Haag
Netherlands	NL-Dordrecht-ASZ	Dordrecht
Netherlands	NL-Ede-ZGV	Ede
Netherlands	NL-Eindhoven-CATHARINA	Eindhoven
Netherlands	NL-Groningen-UMCG	Groningen
Netherlands	NL-Leeuwarden-MCL	Leeuwarden
Netherlands	NL-Tilburg-ETZ	Tilburg
Netherlands	NL-Utrecht-UMCUTRECHT	Utrecht-

Sponsors (3)

Lead Sponsor	Collaborator
Stichting Hemato-Oncologie voor Volwassenen Nederland	German CLL Study Group, Nordic CLL Study Group

Countries where clinical trial is conducted

Belgium,  Denmark,  Germany,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	• Recommended phase II dose (RP2D) for the combination of venetoclax and epcoritamab based on dose limiting toxicity (DLT)	endpoint for phase I and both arms	6-12 months
Primary	• Undetectable minimal residual disease <10-4 (uMRD) in BM in absence of progression according to IWCLL criteria at 12 weeks after cycle 26	endpoint for phase II and both arms	29 months
Secondary	• Minimal residual disease (MRD) status in PB at cycle 4, 6, 9, 12, 15, 18, 21, 24 and 12 weeks after cycle 26; following treatment: every 3 months for the first year, then every 6 months until relapse or until 6 years after registration	both arms	6 years
Secondary	• Progression free survival (PFS), defined as time from registration to the first occurrence of disease progression or death from any cause, whichever occurs first.	both arms	6 years
Secondary	Overall survival (OS), defined as the time from registration to death from any cause.	both arms	6 years
Secondary	Best overall response rate (ORR) defined as the proportion of patients with a complete response (CR), complete response with incomplete marrow recovery (CRi), or partial response (PR) according to IWCLL 2018 criteria.	both arms	6 years
Secondary	• Event free survival (EFS), defined as time from randomization to date start of next CLL treatment, progression or death, whichever comes first.	both arms	6 years
Secondary	• Time to next CLL treatment (TTNT), defined as time from randomization to next new line of treatment.	both arms	6 years
Secondary	• Treatment free survival (TFS), defined as time from date of last protocol treatment to date start of next (new) line of treatment, or death from any cause, whichever comes first.	both arms	6 years
Secondary	Duration of response (DOR), defined as time from first response (i.e., =PR and CR) to PD or death from any cause.	both arms	6 years
Secondary	• Depth (level) of minimal residual disease (MRD) measured in BM after cycle 9 and 12 weeks after cycle 26.	both arms	29 months
Secondary	• Depth (level) of minimal residual disease measured in PB at cycle 4, 6, 9, 12, 15, 18, 21, 24, 12 weeks after cycle 26 and thereafter every 3 months for the first year, then every 6 months until relapse or until 6 years after registration	both arms	6 years
Secondary	Safety parameters: Type, frequency, and severity of- adverse events (AEs) and- adverse events of special interest (AESI) and their relationship to study treatment (determined according to CTCAE v5.0).	both arms	6 years
Secondary	Health-related quality of life (QoL) by EORTC QLQ-C30 questionnaires.	both arms	6 years
Secondary	Health-related quality of life (QoL) by QLQ-CLL17 questionnaires.	both arms	6 years
Secondary	Health-related quality of life (QoL) by PRO-CTCAE questionnaires.	both arms	6 years

External Links

•   Related Info